Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of VHX-896 vs Iloperidone in Healthy Volunteers
NCT04969211Phase 1Completed
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milsaperidone in schizophrenia and bipolar I disorder (2 arms), sponsored by Vanda Pharmaceuticals Inc. Primary endpoints: Bioequivalence between VHX-896 tablets relative to iloperidone tablets at 96 hours and Assessment of Safety and Tolerability of a single dose of VHX-896 at 17 days. Started Jun 2021; status: completed.
02
Drugs
milsaperidone
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT04969211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969211.